Bandingkan Harga & Kinerja Sumber Sinergi Makmur Tbk. (IOTF) vs Tempo Scan Pacific Tbk. (TSPC)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Sumber Sinergi Makmur Tbk. dan Tempo Scan Pacific Tbk.: Sumber Sinergi Makmur Tbk. diperdagangkan di Rp73 (kapitalisasi pasar 333,29 M, volume 24 jam 482,28 jt), sedangkan Tempo Scan Pacific Tbk. diperdagangkan di Rp2.790 (kapitalisasi pasar 12,58 T, volume 24 jam 809,6 rb). Perbedaan utamanya: Tempo Scan Pacific Tbk. jauh lebih besar — sekitar 37,7× kapitalisasi pasar Sumber Sinergi Makmur Tbk., dan Sumber Sinergi Makmur Tbk. lebih aktif diperdagangkan (482,28 jt vs 809,6 rb). Mana yang lebih baik tergantung tujuan investasimu.
| IOTF | TSPC | |
|---|---|---|
Kapitalisasi Pasar | 333,29 M | 12,58 T |
Volume | 482,28 jt | 809,6 rb |
Lot | 4,82 jt | 8,1 rb |
Perputaran | 34,42 M | 2,26 M |
Harga Rata-rata | 71,38 | 2.786,16 |
Nilai Transaksi | 34,42 M | 2,26 M |
Harga Ekuilibrium Indikatif | 73 | 2.790 |
Volume Ekuilibrium Indikatif | 79,4 rb | 1,63 rb |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Sumber Sinergi Makmur Tbk.
PT Sumber Sinergi Makmur Tbk (the Company) was established based on Deed Number 88 dated May 19, 2015 of H. Zainuddin, S.H., a notary domiciled in Jakarta. The company started its commercial activities in 2015. The controlling party of the Company and the party who is the ultimate beneficial owner of the Company is Alamsyah.
Selengkapnya di halaman IOTF →Tentang Tempo Scan Pacific Tbk.
PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.
Selengkapnya di halaman TSPC →
